VOGLIMAC R HD 1 (Repaglinide (1mg) + Voglibose (0.3mg))

Voglimac R HD 1mg/0.3mg Tablet comprises two active components that are employed in the management of type 2 diabetes mellitus. Its primary function is to assist in regulating elevated blood glucose levels following meals. This medication is indicated for individuals who find that other antidiabetic medications, in conjunction with dietary modifications, do not suffice in maintaining glycemic control. The administration of Voglimac R HD 1 should occur immediately after meals, with the specific dosage determined by a healthcare professional. It is crucial to adhere to this treatment plan and avoid discontinuation without consulting your physician, as abrupt cessation could lead to an increase in blood sugar levels, raising the risk of severe complications, including damage to the kidneys and sight. In the event of a missed dose, do not attempt to take the medication between meals; instead, wait until the next meal and follow the usual schedule. Avoid taking an extra dose as compensation for the missed one. This medication is part of a broader management plan that should encompass a nutritious diet, consistent physical activity, and weight management strategies as recommended by your healthcare provider. While side effects may occur, most are transient and resolve independently. Regular monitoring of blood glucose levels is advised during treatment. Prior to initiating therapy, inform your doctor of any existing renal or hepatic conditions, urinary tract infections, or if you are taking diuretics. Pregnant or nursing individuals should seek medical advice before use. Alcohol consumption should be limited as it can heighten the potential for adverse effects.